Key result
Second-line ifosfamide demonstrates good tolerability following doxorubicin progression in metastatic vaginal leiomyosarcoma.
Why the study?
Vaginal leiomyosarcoma is an atypical, rare entity with limited data, often misdiagnosed or detected late, lacking standard treatment protocols.
Population
A 45-year-old patient diagnosed with metastatic vaginal leiomyosarcoma
Comparison
First-line doxorubicin-based chemotherapy followed by second-line ifosfamide-based treatment
Design
Case report
Authors
Loading...
May inform ifosfamide use after doxorubicin progression in rare vaginal leiomyosarcoma; leaves open prospective validation.
Case Report (n=1)
No
Vaginal leiomyosarcoma is a rare malignancy that often presents with nonspecific symptoms leading to delayed diagnosis, highlighting the need for individualized, multidisciplinary care.
Jebrouni et al. (2025) conducted a case report in Primary vaginal leiomyosarcoma (n=1). Doxorubicin followed by ifosfamide was evaluated on Treatment response and tolerance. A 45-year-old woman with metastatic primary vaginal leiomyosarcoma experienced disease progression after first-line doxorubicin but tolerated second-line ifosfamide therapy well.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: